The therapeutic potential of targeting PARPs has led to the development and FDA approval of several PARP inhibitors (PARPi), such as olaparib, which are currently used in the treatment of BRCA-mutation-dependent breast, ovarian, and prostate cancers due to their ability to induce synthetic lethality in tumor cells [2,3]. The gene discussed is PARP1; the disease is neoplasm.